// App-Quantinova.ai

5014 : Early CTC decline as a biomarker of response to treatment in castration-resistant prostate cancer (CRPC): Analysis of the COU-AA-301 and IMMC38 trials.

Researchers

Presenter

  • David Lorente

Principal Investigators

  • David Olmos

  • Joaquin Mateo

  • Arturo Molina

  • Thian Kheoh

  • Robert Thomas Mccormack

  • Howard I. Scher

  • Penelope Flohr

  • Mateus Crespo

  • Ines Figueiredo

  • Susana Miranda

  • Kurt Baeten

  • Tim Pitfield

Medical Centers

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Veridex LLC, Raritan, NJMedical Affairs, Janssen Diagnostics, Beerse, BelgiumThe Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • Development, Menlo Park, CA

  • Veridex LLC, London, United Kingdom

  • Prostate Cancer Clinical Research Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain

Locations

  • United States

  • Spain

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • Alkaline phosphatase

  • Circulating tumor cells

  • Prostate specific antigen

  • Lactate dehydrogenase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved